Table 1.
Prognostication in myelofibrosis includes diverse disease-specific variables that contribute to clinical heterogeneity.
| Lille | IPSS | DIPSS | DIPSSplus | MIPSS70 | GIPSS | MYSEC-PM | |
|---|---|---|---|---|---|---|---|
| Age | X | X | X | X | |||
| Leukocytosis | Xa | X | X | X | X | ||
| Anemia | X | X | X | X | X | X | |
| Symptoms | X | X | X | X | X | ||
| Circulating blasts | X | X | X | X | X | ||
| Thrombocytopenia | X | X | X | ||||
| RBC transfusion dependent | X | ||||||
| Adverse Karyotypeb | X | X | X | ||||
| BMF | X | ||||||
| Non-CALR type 1 | X | X | X | ||||
| HMR = 1 | Xc | Xd | |||||
| HMR > 1 | Xc |
IPSS International Prognostic Scorcing System, DIPSS Dynamic International Prognsotic Scoring System, MIPSS Mutation-Enhanced International Prognostic Scoring System 70, GIPSS Genetically Inspired Prognostic Scoring System, MYSEC-PM Myelofibrosis Secondary to PV and ET-Prognostic Model, RBC red blood cell, BMF bone marrow fibrosis, HMR high molecular risk.
aLeukocytosis and leukopenia are variables in the Lille prognostic Model.
bComplex karyotype or abnormalities including +8, -7/7q-, i(17q), -5/5q-, 12p-, inv(3) or 11q23 rearrangement.
cHMR mutations in MIPSS70: ASXL1, EZH2, IDH1/2, SRSF2.
dHMR mutations in GIPSS: ASXL1, SRSF2, U2AF1Q157.